Biotechnology Sector Report April-2017

11APRIL 2017
BIOTECHNOLOGY
APRIL 2017 (As of 13 April 2017) For updated information, please visit www.ibef.org

22APRIL 2017 For updated information, please visit www.ibef.org
❖ Executive Summary………….…………..…..3
❖ Advantage India……………….………..…….4
❖ Market Overview and Trends….....................6
❖ Strategies Adopted……………….………….16
❖ Growth Drivers…......................................…20
❖ Opportunities………………………………...33
❖ Success Stories: Major Players…….……..38
❖ Useful Information.......................................42
BIOTECHNOLOGY
APRIL 2017

33APRIL 2017
For updated information, please visit www.ibef.org
Source: Department of Biotechnology, Ministry of Science & Technology , Ministry of External Affairs, Government of India, Make In India, TechSci Research
Note: F - Forecast
EXECUTIVE SUMMARY
BIOTECHNOLOGY
By FY25, India’s biotech
industry is estimated to
increase to USD100 billion from
USD7 billion in FY15 and is
currently valued at USD11
billion in FY16.
The biotech industry is
expected to experience
significant growth amid
favourable business conditions
In 12th Five-Year Plan, the
government aims to spend
USD3.7 billion on
biotechnology compared to
USD1.1 billion in the 11th Five-
Year Plan
Increasing government
expenditure is likely to augment
growth in biotechnology
industry.
India’s pharmaceuticals market
size is USD36.7 billion in 2016
and estimated to reach at
USD55 billion in 2020F
Growing pharmaceuticals
market is estimated to aid
growth of the biotech industry
Percentage rise in
investments 236.36%
CAGR: 10.6%
CAGR: 30.46%
USD Billion
1.1
3.7
Eleventh Five Year Plan Twelfth Five Year Plan
USD Billion
USD Billion
7 11
100
FY 15 FY 16 FY 25F
36.7
55
FY 16 FY 20F

55APRIL 2017
Growing demand
ADVANTAGE INDIA
Source: CIS India, Ministry OF External Affairs, Government of India, Ministry of Health,, ABLE,
TechSci Research; Note: E - Estimate
FY16
Market
Value:
USD11
billion
FY25E
Market
Value:
USD100
billion
Advantage
India
BIOTECHNOLOGY
Robust demand
• India’s billion-plus population base offers a
huge market for biotech products &
services
• Increasing economic prosperity and health
consciousness would continue to fuel
demand for healthcare services
• Better accessibility to healthcare services
further accelerates
the demand
Innovation opportunities
• Public funding is being offered for product
innovation and research in the biotech sector
• The private sector has been aggressively
pursuing focused R&D
• Public-Private partnerships will improve the
market with innovative research and
development
• Government of Gujarat aims to create 1 lakh
jobs in the state’s biotechnology industry
Policy support
• In FY15, Ministry of Biotechnology adopted
the open access policy
• In FY16, National Intellectual Property
Rights Policy 2016 has been released
• Research Assistance Council has been set
up
• National Rural Healthcare Mission
launched to boost healthcare spending
• Also, in FY16, DBT launched National
Biotechnology Development Strategy
Increasing investments
• FDI investment up to 100 per cent is
permitted via the automatic route
• A low cost and skilled labour force is
attracting outsourced research activity
• Launch of Biotechnology Industry
Partnership Programme (BIPP) is boosting
industry participation
• In January 2017, 54 MoUs worth USD
767.18 million were signed for projects in
biotechnology sector in Gujarat Global
Summit-2017

MARKET OVERVIEW & TRENDS
BIOTECHNOLOGY

77APRIL 2017
MAJOR MILESTONES IN INDIAN BIOTECHNOLOGY INDUSTRY
Source: EXIM bank of India research, MakeinIndia, Ministry of External Affairs, CII, TechSci Research
Note: R&D - Research and Development, DBT – Department of Biotechnology
BIOTECHNOLOGY
• 1978: India’s 1st biotech firm,
Biocon, was setup
• 1981: Centre for Cellular &
Molecular Biology setup in
Hyderabad
• 1984: Institute for Microbial
Technology, Chandigarh was setup
• 1986: Department of Biotechnology
(DBT) was formed
• 1987: National Institute of
Immunology was setup by DBT
• 1989: Bangalore Genei commenced
operations
• 1991: National Centre for Biological
Sciences pursued R&D in molecular
biology
• 1994: Syngene, India’s 1st Contract
Research Organisation (CRO),
started R&D services
• 1997: Centre for Biological
Technology (CBT) was established
to focus on bioinformatics &
genomics
• 1998: Monsanto Research
established an R&D centre for plant
genomics
• 1998: DBT approved Mahyco-
Monsanto to grow Bt cotton
• 2007: National Biotechnology
Development Strategy launched
• 2007: With the joint efforts of
Government of UP, Department of
Biotechnology & Government of India &
Department of Science & Technology, a
fully functional biotechnology park was
setup in Lucknow
• 2009: National Biotechnology
Regulatory Authority Bill 2008
introduced in the parliament &
Biotechnology Industry Partnership
Programme was launched
• 2010: Cadila Healthcare, Serum Institute
of India & Bharat Biotech launched 1st
H1N1 swine flu vaccine.
1978–90 1990–99 2000-2010

88APRIL 2017
MAJOR MILESTONES IN INDIAN BIOTECHNOLOGY INDUSTRY
Source: EXIM bank of India research, MakeinIndia, Ministry of External Affairs, CII, TechSci Research
Note: R&D - Research and Development
DBT – Department of Biotechnology
BIOTECHNOLOGY
• 2011: Government approved setting up the
Biotechnology Industry Research Assistance
Council (BIRAC)
• 2012: India ranked 12th in the world in biotech &
3rd largest in Asia-Pacific, after Japan & Korea
• 2013: India became the biggest producer of
Hepatitis B vaccine recombinant
• 2015: DBT allocated USD0.735 million to
University of Agricultural Sciences to support a
national multi-institutional project.
• 2015: DBT launched “The National
Biotechnology Development Strategy 2015-
2020 programme” to turn India into
biotechnology hub.
2010-15
• 2016: USD238.09 million was allocated by the
DBT under Budget 2016-17.
• 2016: 8th Biotechnology Industry Research
Assistance Council (BIRAC) announced 8th call
for proposals related to inventions & ideas
under Biotechnology Ignition Grant (BIG)
Scheme.
• 2016: The Regional Centre for Biotechnology
Bill, 2016 was passed by Lok Sabha to impart
training and education under guidance of
United Nations Educational, Scientific &
Cultural Organization (UNESCO).
• 2016: India's National Intellectual Property
Rights policy was launched.
• 2017: Ministry of Health, Malaysia, awarded,
Biocon, a contract worth US$68.43 million to
supply recombinant human insulin formulations
for a duration of 3 years
Post 2015

KEY SEGMENTS IN THE INDIAN BIOTECHNOLOGY INDUSTRY
Source: ABLE - Biospectrum Industry Survey, June 2013; TechSci Research
BIOTECHNOLOGY
• Bio-pharmaceutical
products are
therapeutic or
preventative
medicines that are
derived from
materials naturally
present in living
organisms, using
recombinant DNA
(rDNA) technology
• Bio-services
mainly include
clinical research &
CRO along with
custom
manufacturing
• Bio-agriculture is
segmented into
hybrid seeds,
transgenic
crops, bio-
pesticides & bio-
fertilisers
• Bio-industrial
predominantly
comprises enzyme
manufacturing &
marketing
companies
• Bio-informatics deals
with the creation &
maintenance of
extensive electronic
databases on various
biological systems;
industry
Bio-pharma Bio-services Bio-agri Bio-industrial Bio-informatics
Biotechnology

MAJOR PRODUCTS/SERVICES OF THE INDIAN BIOTECHNOLOGY INDUSTRY
Source: ABLE - Biospectrum Industry Survey, Ministry of External Affairs, TechSci Research
BIOTECHNOLOGY
Biotechnology
Bio-pharma Bio-services Bio-agri Bio-industrial Bio-informatics
Vaccines
Diagnostic
Therapeutic
Custom
Manufacturing
Contract
Research
Organisation
Hybrid seeds
Bio-fertilisers
Bio-pesticides
Industrial
enzymes
Database
services
Integrated
research app
software
Biotech software
services
Clinical Trials

Market size (USD billion)
Source: ABLE - Biospectrum Industry Survey,
Makeinindia, Ministry of External Affairs, TechSci Research
Global Industry Analysts Report (GIA)
Notes: CAGR - Compound Annual Growth Rate
FY16: As of April 2016.
Note: F-Forecast
Growing at a faster pace, in comparison with the previous
years, the Indian biotech industry witnessed YoY growth of
57.14 per cent in FY16; the total industry size stood at
USD11 billion by FY16 and is estimated to reach USD11.6
billion by FY17
Fast-paced growth is likely to continue; the industry is
expected to increase in size to USD11.6 billion by 2017,
driven by a range of factors such as growing demand,
intensive R&D activities and strong government initiatives
The Indian biotech industry comprising about 800
companies is currently valued at USD11 billion. In order to
achieve market size of USD100 billion by 2025, the
Government of India needs to initiate research activities and
develop infrastructure and human capital, with an
investment of US$ 5 billion.
Fast-developing clinical capabilities with the country
becoming a popular destination for clinical trials, contract
research & manufacturing activities
BIOTECHNOLOGY
ROBUST GROWTH IN BIOTECH INDUSTRY
CAGR: 20.33%
1.1
1.5
1.9
2.6 2.6
3
3.8
4.3 4.3
5
7
11
11.6

Market break-up by revenues (FY16)
Source: ASSOCHAM, Makeinindia, TechSci Research
The bio-pharmaceutical segment accounted for largest
revenue share of 64 per cent in India biotech industry,
during FY16.
India is becoming a leading destination for clinical trials,
contract research & manufacturing activities which is
leading to the growth of bio services sector
In FY16, the bio-services & bio-agri segments accounted for
18 per cent & 14 per cent of the biotech industry,
respectively
Serum Institute of India is the largest BioPharma company
in the country & accounts for approximately 22 per cent of
BioPharma market
BIO-PHARMA ACCOUNTS FOR MAJORITY MARKET SHARE AND WITNESSES FASTEST GROWTH IN FY16
BIOTECHNOLOGY
64%
18%
14%
3%
1%
Bio-pharma
Bio-services
Bio-agri
Bio-industry
Bio-
informatics

Source: Department of Biotechnology, TechSci Research
In FY15, provision of USD89.47 million has been made by
Department of Biotechnology for the approved
biotechnology projects in India.
Karnataka is the hub for biotechnology sector. Investments
of USD25.95 million was allocated towards biotechnology
projects in Karnataka. Government of Karnataka planned to
raise USD7.34 million funds for research activities in
biotechnology.
Delhi has the 2nd largest share with 13.26 per cent in FY16.
In FY15, total project cost approved to Delhi is USD11.87
million, allocation of USD22.91 million was made for the
development of science & technology sector in the state.
The funds will be made available to the state by the
Department of Biotechnology (DBT), Earth Science (ES),
Polymer Science & technology (PST), Council of Scientific
& Industrial Research (CSIR), for a period of 5 years
BIOTECHNOLOGY
State wise share for Approved Biotech Project
Cost FY15
STATE WISE SHARE FOR APPROVED BIOTECH PROJECT COST FY15
29.04%
13.26%
11.68%
9.69%
7.76%
6.01%
4.56%
3.30%
14.69%
Karnataka
Delhi
Haryana
Tamil Nadu
Maharashtra
Telangana
West Bengal
Uttar Pradesh
Others

Source: Department of Biotechnology, Government Of
India, TechSci Research
In FY16, 2,621 projects have been received by Department of
Biotechnology which are categorised as ongoing number of
biotechnology projects in India.
Delhi accounted for the largest share of 13.93 per cent of the
total number of projects received in biotechnology sector,
followed by Tamil Nadu, which accounted for a share of
10.95 per cent
In FY16, a total of 365 biotechnology projects were allocated
to Delhi at an approved project cost of USD11.87 million.
As of November 2016, Odisha released the draft of its 1st
Biotechnology policy. The state aims to become one of the
top 5 bio-tech hubs in the country. The state government has
proposed to set up a fund with investment of USD3.73 million
& provide land on priority for setting up of biotechnology
projects
In September 2016, Department of Biotechnology,
Government Of India, decided to set up marine biotech
institute and laboratory in Goa.
BIOTECHNOLOGY
State wise share for Ongoing Number Of Biotech
Projects FY16
STATE WISE SHARE FOR ONGOING NUMBER OF BIOTECH PROJECTS FY16
13.93%
10.95%
9.92%
8.32%
6.64%6.64%
5.80%
3.43%
34.38%
Delhi
Tamil Nadu
Karnataka
Maharashtra
Telangana
Uttar Pradesh
West Bengal
Haryana
Others

Remarkable global
positioning
• India is among the top 12 biotech destinations in the world
• India ranks 2nd in Asia, after China
• India is the world’s largest producer of recombinant Hepatitis B vaccine
• Bharat Biotech commercially launched 1st novel ROTAVAC® vaccine, to eradicate rotavirus
diarrhea, in India.
• While offering tax holidays & investor-friendly environment, Thailand Board of Investment seeks
investments from India in areas such as biotech, automation, etc.
Pharma companies
focusing on biotech
• Ranbaxy, Cadila Healthcare, Lupin, Wockhardt & Dr Reddy’s are among the major Indian
pharmaceutical companies operating in the bio-pharma segment
NOTABLE TRENDS IN THE INDIAN BIOTECH SECTOR
BIOTECHNOLOGY
Global companies
setting up base
• US based DiabetOmics Inc., medical diagnostic company has raised USD4 million from
Ventureast & USD1 million from KI Varaprasad Reddy for driving manufacturing &
commercialization activities in India.
Biosimilars and
molecular diagnostic
remain strongholds
• Growth in the sector is anticipated to come from the country's strong position in biosimilars &
molecular diagnostics as well as personalised medicine (where export & domestic trends look
promising). In 2016, development of biosimilars has been speeding up via Glycosylation Control
Technology.
Source: Ministry of External Affairs, TechSci Research, Indian Law Offices
Bt:
Growth in Genetically
Modified crops
• According to International Service for the Acquisition of Agri-Biotech Applications, India has the 4th
largest area covered under genetically modified crops
• In India, 11.57 million hectares of area is covered under genetically modified crops which is
majorly dominated by Bt cotton.
• After Bt cotton, Bt brinjal, covering an area of 7.6 million hectares, is potentially benefitting farmers
as well as consumers.

STRATEGIES ADOPTED
BIOTECHNOLOGY

STRATEGIES ADOPTED
BIOTECHNOLOGY
• Strand Life Sciences recently collaborated with US-based El Camino Hospital to establish a
genomics & pharmacogenomics centre in San Francisco, while Hyderabad-based GVK Biosciences
entered into an agreement with the US FDA for drug repositioning
• BIRAC in 2016 collaborated with Department of Electronics & Information Technology (DeitY) &
announced call for proposal under Industry Innovation Programme on Medical Electronics (IIPME) to
promote innovative technologies in Medical Electronics sector.
• India’s 1st public-private-partnership agreement was announced between Sun Pharma & Indian
Council of Medical Research (ICMR), Govt. of India, Ministry of Health & Family Welfare (MOHFW),
Govt. of Madhya Pradesh.
• Department of Biotechnology, Department of Science & Technology, Government of India, recently
collaborated with Australian government & announced 4 new research projects in biotechnology
under the Indo Australia Biotechnology Fund.
• Companies in the industry are exploring new avenues in life sciences to strengthen & upgrade the
products & services portfolio through strategic mergers & acquisitions. In 2015, Dr. Reddy’s
Laboratories acquired UCB (India) for USD131.02 million. The acquisition has been done for
established brands of UCB in India, Nepal, Sri Lanka & Maldives
• As of October 2016, Advanced Enzyme Technologies, a biotech based firm in Mumbai signed an
agreement with JC Biotech - Active Pharmaceutical Ingredient (API) maker in Hyderabad, to acquire
70 per cent stake in the company.
• Tata Trusts along with Lockheed, an aerospace major brand has collaborated with Department of
science & technology under the 2nd edition of the India innovation growth programme (IIGP 2.0), to
invest in social & industrial innovations, offer support in incubation, aid in business development &
train innovators in world-class commercialisation strategies.
Strategic collaborations
with niche players and
government bodies
Mergers & Acquisitions
Source: Ministry of External Affairs, RBI; Note: Govt. - Government

STRATEGIES ADOPTED
BIOTECHNOLOGY
• Pharma companies, including Avesthagen, TCG Life Sciences, Advinus Therapeutics & Jubilant
Biosys have stepped up investments in personalised medicine. The idea is to eliminate the
unpredictable nature of drug development through personalized medicine.
• For instance, Xcode Life Sciences uses InDNA technology to provide personalised solutions for
lifestyle-related diseases, such as coronary, diabetes and obesity, using saliva samples.
• Action Biotech provides genetic tests to predict response from chemotherapy drugs. Geneombio
Technologies offer gene-based prediction to assess genetic susceptibility towards major lifestyle
diseases. Acton Biotech, OncQuest Laboratories, etc. are few of the other notable players
operating in the field of personalized medicine in India.
• Companies are evolving their product mix to reflect growing repertoire in Biologics, Branded
Formulations & Research Services
• In FY15, Biocon launched Bionesp, antibody for managing anemia in its early-stage.
• In FY15, Ministry of Science & Technology adopted National Biotechnology Development
Strategy 2015-2020.
Stepped up investment
in personalised
medicine
For ramping up service
offerings
Source: Ministry of External Affairs, RBI

Source: Makeinindia, TechSci Research
SECTOR BENEFITS FROM RISING INCOME AND POPULATION
BIOTECHNOLOGY
Growing demand
Inviting Resulting in
Growing demand Increasing investmentsPolicy support
India’s large
population, a huge
market for biotech
products & services
Higher healthcare
expenditure & an
increase in Bio-agri
products
Strong growth in
export demand & a
rise in medical
tourism
Adoption of Open
Access Policy in
FY15
R&D focus; Indian
government has
been funding
institutes for biotech
research
Rising investments
from domestic &
foreign players
100 per cent FDI
permitted through
automatic route for
manufacturers of
drugs &
pharmaceuticals
Low cost and skilled
labour force
attracting outsourced
research activity
Increase in
budgetary
allocations to the
Biotech & Healthcare
sectors in 5 year
plans

Source: MHRD,
National Biotechnology Development Strategy, DBT, TechSci Research
HIGHER HEALTHCARE EXPENDITURE DRIVING DOMESTIC DEMAND
BIOTECHNOLOGY
Exponential growth in government funding
• Government spending on healthcare, as a percentage of GDP,
for the 12th Five-Year Plan is around 2.5 per cent & to at least 3
per cent of GDP by 2022.
• Government has announced to allocate USD5.43 billion to its
healthcare department. Medical tourism in India has reached
USD3.6 billion in FY2015 & is estimated to reach USD6 billion
by 2018.
• During the 11th Five-Year Plan, the Department of
Biotechnology utilised 94.49 per cent of the allocated resources
• In 2016, government plans to establish 17 new All India Institute
of Medical Sciences & 20 cancer institutes, across the country.
Specialised treatment
• The disease profile that inflicts the Indian population has
experienced a gradual shift. The number of lifestyle-related
diseases being reported is rising; this has led to demand for
various kinds of specialised treatments
• Ailments such as cancer & diabetes have led to a higher
demand for biological products
• Started in 2007, Bugworks Research India has made the
world’s largest Google traffic map for oncology pathways which
is being used by global medical professionals across the globe
for customise treatment for cancer patients. The research firm is
also working on finding solutions to deal with superbug
infections
Preventive healthcare
• Around 1.2 billion ailments are reported annually & this
number is expected to rise at a CAGR of 30 per cent to
15 billion cases by 2015. Better access to healthcare
facilities & rising lifestyle diseases are driving this trend
• Population growth has elevated the vaccine demand
for the geriatric & paediatric population
• In April 2017, scientists from IIT Chennai discovered
that Aspirin, the common headache drug, can cure
cancer
Healthcare Funds availability (USD million)
129.4
302.1
1,354.2
3,726.4
Ninth FYP Tenth FYP Eleventh FYP Twelfth FYP
Source: WHO Statistics 2012
Note: FYP – Five Year Plan

Source: Fortis Healthcare Limited 2008–09, McKinsey Quarterly, NCAER, TechSci Research
RISING INCOME AND INCIDENCE OF CHRONIC LIFESTYLE DISEASES
BIOTECHNOLOGY
Rising income; growing middle class
• Per capita income & rural income are increasing
• The number of middle class households (earning
between USD4,413.1 & USD22,065.3 per annum) is
estimated to increase more than 4-fold to 148 million
by 2030 from 32 million in 2010
• Rising per capita income leads to increased spending
on medical & healthcare services
Higher incidence of chronic lifestyle diseases
• Lifestyle diseases are set to account for a greater part
of the healthcare market
• Lifestyle diseases such as cardiac diseases, cancer &
diabetes are treated with the help of biotechnology
products, thereby boosting revenues of biotech
companies
• The growing GNI per capita, PPP of USD6,030 in FY15
led to improved lifestyle due to increased purchasing
power of customers for healthcare.
Notes: Greater distributional efficiencies and increasing demand (especially
from rural areas) due to rising disposable incomes have created new
markets for products within the country, F - Forecast
Million household, 100%
Income
segment
244 273 322
1% 3% 7%2% 6%
17%23%
25%
29%
43%
40%
32%
30% 26%
15%
2015 2020 2030
Globals(>22065.3) Strivers(11032.7-22065.3)
Seekers(4413.1-11032.7) Aspirers(1985.9-4413.1)
Deprived(<1985.9)

STRONG POLICY SUPPORT CRUCIAL TO THE SECTOR’S DEVELOPMENT
BIOTECHNOLOGY
Source: “Biotechnology facilities,” Department of Biotechnology, TechSci Research, Note: BIRAC - Biotechnology
Industry Research Assistance Council
Programme for SC/ST
and Rural Population
• Training & demonstration programme in various biotechnology based activities were undertaken
to empower the population resulting in socioeconomic upliftment
Single-window
clearance
• As per NBDS, a proposal has been made to set up the National Biotechnology Regulatory
Authority (NBRA) to provide a single-window clearance mechanism for all bio-safety products to
create efficiencies & streamline the drug approval process
Biotechnology Industry
Research Assistance
Council
• BIRAC has been established to promote research & innovation capabilities in India’s biotech
industry
• Under BIRAC, the government will provide funding to biotech companies for technology & product
development.
• BIRAC under Small Business Innovation Research Initiative (SBIRI) scheme supports innovations
in biotechnology.
Tamil Nadu Bio
technology Policy 2014
• The Policy aims to encourage new companies to operate in Tamil Nadu, thereby increasing the
R&D & manufacturing activities in the sector
Biotechnology Based
Programme for Women
• Programme on application of biotechnology for women was done to provide employment, skill
development, awareness generation, health improvement & socio-economic upliftment of the
women population
“Biotechnology Policy
2015-2020 “
(Andhra Pradesh)
• The Policy has been formulated to promote biotechnology sector in Andhra Pradesh. The new
policy covers the benefits for the following categories: Incubation Centres, Biotech manufacturing
industries, Life Science Park, Life Science Knowledge Centre, Research & Development Centres.
State Biotechnology
Policy
(2016-2021) (Gujarat)
• Financial incentives of up to USD3.81 million & capital assistance of up to USD7.63 million would
be given to biotechnology parks & biotechnology companies. Moreover, for new biotechnology
finishing schools, the government has decided to allocate USD 0.15 million.

12th Five-Year Plan expenditure (USD billion)
Source: Deptt. of Science and Technology, TechSci Research
The overall strategy of 12th Five-Year Plan is to accelerate the
pace of research, innovation & development. The main
objective is to advance biotechnology as strategic area by
taking India’s strengths in foundational sciences to globally
competitive levels. In addition, emphasis is on expanding the
application of biotechnologies for overall growth of bio-
economy within the framework of inclusive development
The 12th Five-Year Plan aims to accelerate the pace of
research, innovation & development to improve biotechnology
in India.
The government plans to strengthen regulatory science &
infrastructure, which involves setting up the Biotechnology
Regulatory Authority of India (BRAI) & a central agency for
regulatory testing & certification of laboratories
The plan also entails expanding & commissioning new
bioclusters at Faridabad, Mohali Kalyani & Hyderabad
It aims to encourage & increase the pool of research scholars &
scientists by three-fivefold in biological & interdisciplinary space
across levels (PhD, PDFs, young faculty)
Central Government approved development of 6 new IT & Bio-
Tech SEZs, from 4 developers for across 3 states. As of 31st
March 2016, Special Economic Zones attracted investments
worth USD57439 million.
BIOTECH IN FOCUS IN 12TH FIVE-YEAR PLAN
BIOTECHNOLOGY
1.1
3.7
Eleventh Five Year Plan Twelfth Five Year Plan
12th Five-Year Plan fund allocation (USD billion)
26%
22%
17%
14%
21%
Medical biotech
Agri biotech
Basic bio & emerging areas
Biodiversity, bioresources &
Environment
Capacity building

Joint Venture fund
• In February 2015, Aurobindo Pharma announced a Joint Venture with Tergene Biotech company for cost
effective development of the Pneumococcal Conjugate Vaccine (PCV).
• Government funding is crucial for biotech industry due to limited access to other sources of funding.
Infrastructure
development
• India’s central government & state governments, in collaboration with private players, continue to develop
new infrastructure facilities, especially at biotechnology parks
• The government is developing 3 major biotech clusters at Mohali in Punjab, Faridabad in Haryana &
Bengaluru in Karnataka. It plans to set up an agri-biotech cluster in Pune (Maharashtra) & Kolkata (West
Bengal)
GOVERNMENT FUNDING CRUCIAL FOR THE BIOTECH INDUSTRY
BIOTECHNOLOGY
International
collaborations
• India has partnered with countries such as the UK, Russia, Italy, the US and France to enable knowledge
transition.
• In 2015, the UK Medical Research Council (MRC) and the Government of India Department for
Biotechnology (DBT) formed an alliance to fund three major global research centers
• In 2016, a cooperation agreement with European Molecular Biology Organization (EMBO) was signed by
the Government of India to enhance collaborative research activities between India and Europe.
Clinical
Establishments Bill
• In a move to standardise procedures, the Indian Parliament passed the Clinical Establishments Bill 2010,
which would make registration of clinical trials as well as clinical research organisations mandatory in the
country
• The Bill also includes standard operating procedures for various trial related tasks
• Government plans to fast track the approval process for clinical trials while ensuring that CROs involved
comply with stricter quality and compliance checks.
Source: Ernst & Young, TechSci Research; Note: DST-Department
of science and Technology, DBT-Department of Biotechnology
Research Funding
Agency
• The DST has consistently enabled transformational changes through appropriate responses & non-
participative roles. DST accordingly played the role of an extra mural research funding agency wherein
competitive grants for research was provided to investigators based on technical merit. In 2015, DBT &
Tekes (Finland) joined to form an alliance to fund international standard joint projects to address Indian &
global needs

CENTRE AND STATE GOVERNMENT INITIATIVES PROVIDE BIG BOOST TO BIOTECH INDUSTRY
BIOTECHNOLOGY
Increasing government support
International collaboration of Department of Biotechnology with other countries
100 per cent foreign equity investment is possible in manufacturing of all drugs
except recombinant DNA products & cell targeted therapies
Single window processing mechanism for all biotech projects involving FDI
Depreciation allowance on plant & machinery raised to 40 per cent from 25 per
cent
Customs duty exemption on goods imported in certain cases for R&D
Customs & excise duty exemption to recognised Scientific & Industrial Research
Organisations (SIRO)
150 per cent weighted tax deduction on R&D expenditure
Three years excise duty waiver on patented products
100 per cent rebate on own R&D expenditure
125 per cent rebate if research is contracted in public funded R&D institutions
Joint R&D projects provided special fiscal benefits
The National Biotechnology Development Strategy 2015-20 to make India bio-
manufacturing hub.
Promote innovations through BIPP, SBIRI, BIRAC & Biotech parks
Adoption of new Open Access Policy in FY15
Favourable IP climate
Indian Copyright Act, 1957
The Patent Act, 1970
Indian Patents and Design Act, 1972
The Trademarks Act, 1999
Biotechnology Patent Facilitating Cell (BPFC)
Foundation of Biotechnology Awareness & Education
(FBAE)
National Research Development Corporation (NRDC)
National Guidelines for Stem Cell Research (2013)
Tamil Nadu Biotechnology Policy 2014
Biotechnology Policy 2015-2020, Andhra Pradesh
National Intellectual Property Right Policy 2016
Source: Ernst & Young, TechSci Research
Notes: BIPP - Biotechnology Industry Partnership Programmes,
SBIRI - Small Business Innovation Research Industry,
BIRAC - Biotechnology Industry Research Assistance Council,
IP – Intellectual Property

REGULATORY FRAMEWORK OF THE INDIAN BIOTECH SECTOR
BIOTECHNOLOGY
Source: Policy and rules, Department of Biotechnology website,
TechSci Research
Government of India
Ministry of Science
& Technology
Ministry of
Environment &
Forests
Department of
Biotechnology
Department of
Environment, Forests
& Wildlife
Recombinant DNA
Advisory Committee
(RDAC)
Regulatory Committee
on Genetic
Manipulation
(RCGM)
Institutional Biosafety
Committee
(IBSC)
Genetic Engineering
Approval Committee
(GEAC)

Source: Press Information Bureau, TechSci Research
The 12th Five Year Plan (2012–17) aims to set up 3–5 bio-
clusters with technology incubators, technology parks,
innovation centres & entrepreneurship development units
Biotechnology infrastructure is witnessing a shift from
traditional clusters to specialised industrial infrastructure
such as biotech or science parks
States such as Karnataka, Andhra Pradesh, Maharashtra,
Tamil Nadu & Kerala have been early movers in
establishing world-class biotech parks and clusters.
In 2016, Monsanto, a leading player in global
biotechnology industry planned to establish a seed plant in
Buldhana district of Maharashtra.
Investors such as TCG Bio-pharma & Alexandria have
significantly contributed to the establishment of
biotechnology-related infrastructure in India.
Science & Technology Department has acquired 10 acres
of land in Jammu & Kashmir to set up 1st biotechnology
park in the state.
Life sciences & advanced biotechnology committee,
economic development board & the Government of Andhra
Pradesh, is planning to develop a biotechnology research
park to develop the state as a biotech hub.
SOLID INDUSTRY INFRASTRUCTURE WOULD DRIVE GROWTH
BIOTECHNOLOGY
Jogindernagar
Shimla
Chandigarh
AlwarSohna
Jodhpur Jaipur
Gandhinagar
Anand
Jamnagar
Baroda
Aurangabad
Pune
Hyderabad
Bhubaneshwar
Konark
Midnapore
Pantnagar
Bengaluru
Chennai
Puducherry
Visakhapatnam
Kochi
Karwar
Madurai
Operational biotech parks

2929APRIL 2017
Research parks
Communities generating innovation, technology and knowledge
Knowledge of existing firms commercialisation of intellectual
property
Creation of new companies
Research partners
Flow of talent
Exchange of ideas
Access to laboratories and
specialised equipment
Universities
Govt. research
laboratories
Other R&D
institutions
Private firms
Job and income generation
Source: Research and Information System
for Developing Countries (RIS), TechSci Research
CONCEPT OF BIOTECH PARK
BIOTECHNOLOGY
The flow of job and income generation in biotechnology, through involvement of public & private initiatives with proper
utilisation of available resources, is explained in the following diagram:

3030APRIL 2017
for Developing Countries (RIS), TechSci Research, "Mid-term appraisal“
Fellowships rose from 100 to 250 per year for PhD students, in addition
to 100 postdoctoral & 50 biotechnology overseas associateships
Government provided grant-in-aid to the industry for R&D in certain
diseases such as malaria & leishmaniasis or kala-azar
HIGH-END RESEARCH INFRASTRUCTURE CREATES SCOPE FOR INNOVATION
BIOTECHNOLOGY
Details of key biotechnology parks in India
Parks City Area (in acres)
Shapoorji Pallonji Biotech Park Hyderabad 300
ICICI Knowledge Park Hyderabad 200
International Biotech Park Pune 103
Lucknow Biotech Park Lucknow 20
Golden Jubilee Biotech Park Chennai 8
Ticel Bio Park Chennai 5
Key research institutes in India
Central Drug Research Institute (CDRI), Lucknow
National Institute of Pharmaceutical Education & Research
(NIPER), Mohali
Indian Institute of Chemical Technology (IICT), Hyderabad
Centre for Cellular & Molecular Biology (CCMB),
Hyderabad
Indian Institute of Chemical Biology (IICB), Kolkata
Indian Toxicology Research Institute (ITRI), Lucknow
Institute of Genomics and Integrative Biology (IGIB), New
Delhi
Institute of Microbial Technology (IMTECH), Chandigarh
National Chemical Laboratory (NCL), Pune
National Centre for Biological Sciences (NCBS), Bengaluru
Jawaharlal Nehru Centre for Advanced Scientific Research
(JNCASR), Bengaluru
Indian Institute of Science (IISc), Bengaluru
National Institute of Immunology (NII), New Delhi
National Center for Cell Sciences, Pune
National Center for Plant Genome Research (NCPGR),
New Delhi
List of Biotech Parks at Developing Stage
Parks City Area (in acres)
Guwahati Biotech Park Assam 700
KINFRA Biotech Park Kerala 75
Bio Pharma-IT Park, Odisha 64.61
Bangalore Biotech Park Karnataka 53

3131APRIL 2017
for Developing Countries (RIS), TechSci Research, "Mid-term appraisal“
Department of Biotechnology supports various biotech facilities in the nation, which is driving the biotechnology industry by
providing advanced research infrastructure.
Various biotech facilities have been established by Department of Biotechnology under “Task Force on Research
Resources, Service Facilities and Platforms”.
HIGH-END RESEARCH INFRASTRUCTURE CREATES SCOPE FOR INNOVATION
BIOTECHNOLOGY
List of Key Biotechnology Facilities in India Supported by DBT
Facility Established Name of the Institution Sanction Year
Animal House facility
National Institute of Immunology (NII), New Delhi 2013
Translational Health Science & Technology Institute (THSTI), Faridabad 2014
Indian Institute of Scientific Education & Research (IISER) – Knock Out &
Transgenic Mice, Pune
2016
Indian Institute of Science (IISc), Bengaluru 2016
High Resolution Mass
Spectrometry Facility
Indian Institute of Bombay, Mumbai 2016
Containment Facilities
Tuberculosis Aerosol Challenge Facility, International Centre for Genetic
Engineering & Biotechnology (ICGEB), New Delhi
2016
Flowcytometry, Imaging and
Microarray Facilities
Electron Microscopy Referral Facility, Govind Ballabh Pant Institute of
Postgraduate Medical Education & Research, Delhi
2015

STRONG INFLOW OF FOREIGN INVESTMENT
BIOTECHNOLOGY
Date
announced
Acquirer name Target name
Value of deal
(USD million)
Sept 2016 Bayer Mosanto 2,830
Jan 2016 Venaxis Strand Life Sciences -
Oct 2015 Recipharm CMO Nitin Lifesciences 109.92
July 2015 Lupin Limited Gravis Pharmaceuticals LLC 800
Dec 2014 Leaders Group Asia Ltd Dr Datsons Labs Ltd -
Oct 2014 B Braun Singapore Pte Ltd Ahlcon Parenterals (India) Ltd 7.89
May 2014 Cancer Genetics Inc Bioserve Biotechnologies 1.9
May 2014 Anglo Gulf Ltd SciGen BioPharma Pvt Ltd 7.00
Jan 2014 Lotus Pharmaceutical Co Ltd Alvogen Pharma India Pvt Ltd 10.00
Oct 2013 Innovation Software Exports Agrata Biotech Ltd -
May 2013 Bio Harvest Pte Ltd Camson Bio Technologies Ltd 51.06
Dec 2012 Malabar Trading Co Ltd SPL Biotech Pvt Ltd -
Oct 2012 GE Equity International Syngene International Ltd 302.13
Jun 2012 Nandan Cleantec PLC Xtraa Cleancities Infra -
Mar 2012 Origio A/S Trivector Scientific Pvt Ltd 8.61
Aug 2011 DMV-Fonterra Excipients GmbH Brahmar Cellulose Products -
Aug 2011 Arvind Remedies Ltd Undisclosed Pharmaceutical Co -Source: Thomson One Banker, TechSci Research

Vaccines
• Vaccines & recombinant therapeutics are the sectors driving the biotechnology industry’s growth in India
• Newer therapies are anticipated to be launched in the next few years; prominent among these are
monoclonal antibodies products, stem cell therapies and growth factors
• The country’s huge population makes it among the world’s largest markets for vaccines. In 2015, Bharat
Biotech launched ‘Rotavac’ vaccine in India, three doses of the vaccine can prevent the Rotavirus
diarrhea in infants.
• Indian pharmaceutical firms supply 80 per cent of the anti retroviral drugs to fight AIDS globally
• As on October 2016, Sun Pharmaceutical Industries Ltd & International Centre for Genetic Engineering
& Biotechnology (ICGEB) signed a pact to develop vaccine for all four serotypes of dengue virus.
HUGE OPPORTUNITIES FOR INNOVATION IN AGRICULTURE/HEALTHCARE
BIOTECHNOLOGY
Bioactive therapeutic
proteins
• Protein & antibody production & fabrication of diagnostic protein chips are promising areas for
investment
• Stem cell research, cell engineering & cell-based therapeutics are other areas, where India can cash its
expertise
Agriculture sector
• India has the potential to become a major producer of transgenic rice & several Genetically Modified
(GM) or engineered vegetables
• Hybrid seeds, including GM seeds, represent new business opportunities in India based on yield
improvement
• Growing at an annual growth rate of 10-15 per cent, the Indian hybrid seed industry is estimated at
USD1.93 billion in FY16, wherein Bt cotton is leading the market accounting for 45 per cent share India
hybrid seed industry.
Source: India Law Offices, TechSci Research
Intellectual Property
• Using the patent system as a mechanism to control drug pricing forestalls making the difficult decisions
about necessary investment in the healthcare system, but does not deal with the underlying issues.

Bio services Sector
• Beyond biothereapeutics, the bioservices sector represents an area of significant promise for India
because of its skilled labour force, attractive costs & access to major markets in Asia.
• In FY16, Bio services was the 2nd largest sector in India’s biotechnology industry with 18 per cent
market share & accounted for market size of USD1.98 billion.
• India’s bioservices sector includes global contract research organisations, such as Quintiles, as well as
Indian companies including GVK Bio, Jubilant Biosys & Advinus.
HUGE OPPORTUNITIES FOR INNOVATION IN AGRICULTURE/HEALTHCARE
BIOTECHNOLOGY
Bio Pharmaceutical
Industry
• As the cost of bringing new molecules from discovery to market continues to rise, the global
biopharmaceutical industry is seeking ways to improve efficiency.
• The Department of Pharmaceuticals, Government of India planned to introduce venture capital fund of
USD146.72 million to fasten growth in biotech & pharmaceutical industry.
Manufacturing
• Manufacturing is also an area where India is leveraging its cost-competitiveness.
• India has the opportunity to replicate in biologics the same type of success it has had with small
molecule drugs.
• Indian Immunologicals Ltd (IIL) plans to set up a new vaccine manufacturing facility in Pondicherry
with an investment of USD47.99 million
Source: India Law Offices, TechSci Research, Ministry of External Affairs
Bioinformatics
• The convergence of the life sciences with information technology is creating a particular opportunity for
India.
• The country has well-established strengths in the information technology area & with the advent of
low-cost, whole genome sequencing & the growing role of molecular diagnostics in both precision &
preventive medicine, there is a proliferation of data creating demand for bioinformatic analysis.

Contract
research
• The R&D sector has huge potential; many opportunities have been created with a number of foreign
companies investing in this sector
• Indian pharmaceutical companies possess competitive skills in chemical synthesis & process engineering;
the companies can leverage these skills to develop new chemical entities
OUTSOURCING OPENS UP FURTHER AVENUES FOR GROWTH OF BIOTECH
BIOTECHNOLOGY
Clinical trials
• India offers a suitable population for clinical trials because of its diverse gene pools, which cover a large
number of diseases
• Cost effectiveness, competition & increased confidence on capabilities and skill sets have propelled many
global pharmaceutical companies to increase their clinical research investment in the nation
International
collaboration
• Memorandum of Understanding (MOU) have been signed with Denmark & Finland & joint call for
proposals have been issued
• Joint projects have also been funded with the Biotechnology & Biological Sciences Research Council
(BBSRC), UK
• New agreements on vision research with National Institutes of Health (NIH), USA & an amendment to the
agreement with Contraceptive Research and Development Programme (CONRAD)
• In 2015, DBT announced Indo-Australian Gold Fellowships to support researches to undertake
collaborative research project in Australia for 24 months.
Source: India Law Offices, Deptt. of Biotechnology, TechSci Research
Others
• Other potential areas of development include medicinal, aromatic plants, animal biotechnology,
aquaculture, marine biotechnology, seri biotechnology, stem cell biology, environmental biotechnology,
biofuels, biopesticides, human genetics & genome analysis

Market size (USD million)
Source: Deptt. of Biotechnology,
Marketresearch, ABLE, TechSci Research
Note: E - Estimates
India was the 1st country in the world to establish a
Biotechnology Information System (BTIS) network in 1987.
This facilitated development of bioinformatics that has
provided support to the biotechnology sector
Bioinformatics research is poised to become one of the
fastest emerging markets in India
Bioinformatics is estimated to rise at a CAGR of 34.92 per
cent to USD2.7 billion during FY12–25
India currently has close to 10 per cent of the global
professional and skilled bioinformaticians
With 10 per cent of the global professional & skilled
bioinformaticians, Indian bioinformatics companies can play
a significant role in critical areas such as data mining,
mapping and DNA sequencing
There is also opportunity in functional genomics, proteomics
& molecule design simulation
In July 2016, government allowed setting up of
bioinformatics units in residential areas
BIOINFORMATICS TO GROW CONSIDERABLY
BIOTECHNOLOGY
CAGR: 34.92%
55 140
2,700
FY12 FY15 FY25E

BIOCON: AN EARLY MOVER IN THE GLOBAL BIOTECH MARKET
Biocon’s position in the Indian market during FY15–16
• Biocon received an award Greentech Environment Gold
Award for Excellence in Environment Management
• Pharmexcil Gold Patent Award
• Golden Peacock Award for CSR
• Biocon Foundation is recognized for Outstanding
• Contribution to Public Health by WHO India
Revenue and net profit (USD million)
Source: Biocon Annual Report 2016
BIOTECHNOLOGY
• Incorporated
in 1978 at
Bengaluru,
India
• IPO
offering in
2004 (BSE,
NSE India)
• Among the
world’s largest
producers of
statins &
immunosuppr
essants
• 2011:
Launched
INSUPen®, a
convenient &
affordable
reusable
insulin
delivery
device
• Market cap of
USD3.39 billion in
FY16
• Revenue in FY16
stood at
USD545.4million
while net profit
totaled USD81.5
million
• Initiated trials for
IN-105 (oral insulin
program) in the US
• Tied-up with Quark
Pharmaceuticals to
develop novel
siRNA-based
therapeutics
• Partnered with
Advaxis to develop
a novel cancer
immunotherapy
• 2016: Biocon’s
biosimilar Insulin
Glargine was
granted
regulatory
approval in Japan
& is estimated to
be launched in
Q1 FY17.
• 2016: 1st generic
formulation,
Rosuvastatin
Tablets was
granted
European
approval & is
estimated to be
launched in FY17
with company
benefitting from
an expected
revenue of
USD1.2 billion.
260.0
315.0
408.0
448.0
467.3
486.6
514.7
545.4
FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16
Revenue Net Profit

SERUM INSTITUTE OF INDIA: GAINING GLOBAL GROUND
Source: Company website, ABLE, TechSci Research
BIOTECHNOLOGY
Serum Institute recognised
as the world's largest
producer of vaccines for
Measles & DTP
Strong
presence in Bio
Pharma
space
Company sells
products in 140
countries worldwide
Serum Institute sold
around 1.3 billion
vaccines doses in
2015
Generated revenue of
USD600 million
in FY16
Started operations with
manufacturing of Tetanus
Antitoxin, followed by
Tetanus Toxoid
Commenced export of
vaccines to UN agencies;
export crosses over a 100
countries
Focused on gaining R&D
edge, global market reach
and wide product portfolio
Focus on
R&D
Launched India's
first MMR
Vaccine Tresivac
One out of every two
children in the world
vaccinated by Serum
Institute’s vaccine
Recognised as
India's number
one bio-tech
company for 2
consecutive
years
1967 1994–2000 2005–16
Launched the
world's only
adsorbed liquid
HDC Rabies
vaccine
Serum Institute
has bought selling
rights from Biotech
Visterra VIS513
antibody for
dengue
Serum Institute to
distribute BCG-based TB
vaccine in India, originally
developed in Germany
2016

PANACEA BIOTECH: FOCUS ON INNOVATION AND R&D
Source: Company website, TechSci Research
BIOTECHNOLOGY
India’s 3rd largest
Biotech company with
presence in more than
35 countries
worldwide
More than 1,510
patent applications filed
globally; of this, 415
have been granted
In FY10–11, revenues
grew 32% to USD203.7
million
Generated revenue of
USD99.77 million
in FY16
Established plant for vaccine
production at New Delhi
under the name Radicura
Pharma
Merged Panacea Drugs &
Radicura Pharma to form
Panacea Biotec Ltd &
launched IPO in 1995
Forayed into Healthcare
Delivery; entered into a
collaboration to set up 220-
bed multi-super specialty
hospital & a R&D centre in
Delhi
Strategic alliance
with Kremers Urban
for entry into
generics
Approval for
development &
commercialisation of
Anthrax vaccine
1988 1994–2000 2005–16
Selected by WHO for
developing the sabin
based injectable polio
vaccine
Started drug
delivery R&D
centre at Lalru
Licensing agreement
with National Institute
of Health, US, for hair
growth hormone
2004
Started new state-of-
the-art Oncology
centre at Baddi
Launched anti-
diabetic drug
“Tenepan”
2016
Launched
“CABAPAN” for
treatment of mCRPC
2016
Note: mCRPC stands for metastatic Castration
Resistant Prostrate Cancer

USEFUL INFORMATION
BIOTECHNOLOGY

4343APRIL 2017
INDUSTRY ASSOCIATIONS
BIOTECHNOLOGY
Association of Biotechnology Led Enterprises (ABLE)
# 123/C, 16th Main Road, 5th Cross, 4th Block
Near Sony World Showroom/Headstart School
Koramangala, Bengaluru – 560034
Phone: 91 80 41636853 25633853
E-mail: info@ableindia.org
Website: www.ableindia.org
All India Biotech Association (AIBA)
"VIPPS Center" 2. Local Shopping Centre Block EFGH, Masjid Moth,
Greater Kailash-II, New Delhi-110048
Tel: 91 11 29211487 (Direct), 29220546/547
Fax: 91 11 29223089, 29229166
Email: unmalik@aibaonline.com
Website: www.aibaonline.com

4444APRIL 2017
GLOSSARY
Bt: Bacillus thuringiensis
CAGR: Compound Annual Growth Rate
CRO: Contract Research Organisation
DNA: Deoxyribonucleic acid
FYP: Five Year Plan
GCP: Good Clinical Practice
INR: Indian Rupee
NBTB: National Biotechnology Board
OAD: Oral Anti-diabetic Drugs
R&D: Research And Development
FY: Indian Financial Year (April to AUGUST)
So FY10 implies April 2009 to AUGUST 2010
USD: US Dollar
Wherever applicable, numbers have been rounded off to the nearest whole number
BIOTECHNOLOGY

4545APRIL 2017
Exchange rates (Fiscal Year)
EXCHANGE RATES
Exchange rates (Calendar Year)
BIOTECHNOLOGY
Year INR equivalent of one USD
2004–05 44.81
2005–06 44.14
2006–07 45.14
2007–08 40.27
2008–09 46.14
2009–10 47.42
2010–11 45.62
2011–12 46.88
2012–13 54.31
2013–14 60.28
2014-15 61.06
2015-16 65.46
2016-2017E 66.95
Source: Reserve bank of India,
Average for the year
Year INR equivalent of one USD
2005 43.98
2006 45.18
2007 41.34
2008 43.62
2009 48.42
2010 45.72
2011 46.85
2012 53.46
2013 58.44
2014 61.03
2015 64.15
2016 (Expected) 67.22

4646APRIL 2017
India Brand Equity Foundation (“IBEF”) engaged TechSci to prepare this presentation and the same has been
prepared by TechSci in consultation with IBEF.
All rights reserved. All copyright in this presentation and related works is solely and exclusively owned by IBEF. The
same may not be reproduced, wholly or in part in any material form (including photocopying or storing it in any
medium by electronic means and whether or not transiently or incidentally to some other use of this presentation),
modified or in any manner communicated to any third party except with the written approval of IBEF.
This presentation is for information purposes only. While due care has been taken during the compilation of this
presentation to ensure that the information is accurate to the best of TechSci and IBEF’s knowledge and belief, the
content is not to be construed in any manner whatsoever as a substitute for professional advice.
TechSci and IBEF neither recommend nor endorse any specific products or services that may have been mentioned in
this presentation and nor do they assume any liability or responsibility for the outcome of decisions taken as a result of
any reliance placed on this presentation.
Neither TechSci nor IBEF shall be liable for any direct or indirect damages that may arise due to any act or omission
on the part of the user due to any reliance placed or guidance taken from any portion of this presentation.
DISCLAIMER
BIOTECHNOLOGY

Biotechnology Sector Report April-2017

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Ähnlich wie Biotechnology Sector Report April-2017

Ähnlich wie Biotechnology Sector Report April-2017 (20)

Mehr von India Brand Equity Foundation

Mehr von India Brand Equity Foundation (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Biotechnology Sector Report April-2017